Interleukin-15 (IL-15) and BDNF are two key mediators of these effects, since they increase in the brain of EE mice, and their in situ administration reduces tumour size in glioma-bearing mice, similarly to EE. This evidence concerns the gene BDNF and central nervous system cancer.